Which 14 Peptides Are Becoming Legal Again in 2026? Complete List

On February 27, 2026, HHS Secretary RFK Jr. announced that 14 of the 19 peptides banned in 2023 are moving from Category 2 (prohibited compounding) back to Category 1 (legal for compounding pharmacies). This comprehensive guide lists all 14 peptides, explains what each one does, why it was banned, and the scientific evidence supporting its reclassification.

The Complete List of 14 Reclassified Peptides

Here is the definitive list of all 14 peptides that are being reclassified from Category 2 to Category 1, organized by therapeutic category:

Growth Hormone Secretagogues (GHS): Ipamorelin, GHRP-2, GHRP-6

Growth Hormone-Releasing Peptides: CJC-1295

Tissue Repair and Recovery: BPC-157, TB-500 (Thymosin Beta-4)

Immune Modulators: Thymosin Alpha-1, Selank, Semax

Sexual Function: PT-141

Structural and Metabolic Support: GHK-Cu, AOD-9604, KPV, MOTS-c

Each of these peptides has a distinct mechanism of action, therapeutic application, and scientific evidence base. Let's explore each one in detail.

Growth Hormone-Related Peptides: GHS and GHRH Analogues

Ipamorelin is a growth hormone secretagogue that stimulates the pituitary gland to produce and release more growth hormone. Unlike exogenous growth hormone injection, Ipamorelin works with your body's natural signaling, making it a gentler approach to optimizing growth hormone levels. It's particularly popular among aging adults seeking to maintain muscle mass, reduce body fat, improve sleep quality, and support recovery. Ipamorelin was banned in 2023 despite strong safety data from numerous clinical studies. The reclassification reflects recognition that when used under medical supervision with appropriate monitoring, it poses minimal risk while offering significant potential benefits.

GHRP-2 (Growth Hormone-Releasing Peptide-2) is another growth hormone secretagogue that works synergistically with CJC-1295 and other peptides. It stimulates growth hormone release and has been studied for its potential in improving lean muscle mass, reducing body fat, and supporting metabolic health. GHRP-2 has a longer history of research than many newer peptides, with studies dating back decades. The ban was considered overly cautious given the extensive safety data. Now reclassified, GHRP-2 can be legally prescribed and compounded for patients seeking natural growth hormone optimization.

GHRP-6 is similar to GHRP-2 but has a slightly different profile and application. It also stimulates growth hormone secretion and is often stacked with other peptides for synergistic effects. Some patients prefer GHRP-6 over GHRP-2 due to differences in side effect profiles or individual responsiveness. The reclassification means healthcare providers can now choose the most appropriate GHRP variant for each patient's needs.

CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analogue that is typically administered once per week. It works by stimulating the hypothalamus and pituitary to increase growth hormone production. When combined with GHRP peptides, it provides a comprehensive approach to natural growth hormone optimization. CJC-1295 has been extensively studied and is considered one of the safest peptides available. Its reclassification was somewhat surprising given its strong safety profile, but it was caught in the blanket 2023 ban. Now it's legal again for qualified patients with prescriptions.

Tissue Repair and Recovery: BPC-157 and TB-500

BPC-157 (Body Protection Compound-157) is perhaps the most celebrated peptide in the reclassification announcement. It's a 15-amino acid peptide naturally found in gastric juices that supports tissue repair and healing. Extensive research shows BPC-157 promotes wound healing, supports gut health, facilitates collagen deposition, and may help with joint and tendon recovery. Athletes, fitness enthusiasts, and individuals recovering from injury have reported remarkable results with BPC-157. The scientific literature supporting it is substantial, making its 2023 ban seem particularly unjustified. The 2026 reclassification finally allows physicians to prescribe it legally to their patients seeking tissue repair and recovery.

TB-500, also known as Thymosin Beta-4, is a naturally occurring peptide involved in muscle development, recovery, and repair. It upregulates actin, a protein crucial for cellular structure and muscle growth. TB-500 has been studied for applications in muscle injury recovery, athletic performance, and overall musculoskeletal health. Like BPC-157, TB-500 has strong scientific support. The peptide is particularly valued by athletes and those recovering from orthopedic injuries. Its return to Category 1 status means healthcare providers can now prescribe it as part of comprehensive recovery protocols.

Immune-Supporting Peptides: Thymosin Alpha-1, Selank, and Semax

Thymosin Alpha-1 is a naturally occurring peptide produced by the thymus gland that plays a critical role in immune function. It enhances T-cell mediated immunity, supports the body's defense against infections, and may have applications in cancer immunotherapy. Thymosin Alpha-1 has been studied in clinical trials for various infectious diseases and immune-related conditions. It's actually approved as a pharmaceutical in some European countries for specific medical indications. Its inclusion in the 2023 ban was controversial given its clinical legitimacy and immune-supporting properties. The reclassification allows American physicians to now use it in clinical practice.

Selank is a Russian-developed peptide with decades of research behind it. It's known for its neuroprotective, anxiolytic (anti-anxiety), and immunomodulatory properties. Studies suggest Selank supports emotional resilience, cognitive function, and immune health. It appears to work by influencing neurotransmitter systems and immune signaling. In Russia and Eastern Europe, Selank has been prescribed for anxiety, depression, and immune support for many years. Its reclassification brings it into the American mainstream medical market where it can now be legally prescribed and compounded.

Semax is another Russian peptide with strong research behind it showing neuroprotective and cognitive-enhancing properties. It may support memory, learning, attention, and overall brain health. Semax works through mechanisms involving neurotrophic factors and brain-derived neurotrophic factor (BDNF). Athletes, students, and individuals seeking cognitive enhancement have anecdotally reported benefits from Semax. Like Selank, its reclassification brings this well-researched Russian peptide into legal availability for American patients.

Sexual Function Support: PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is notable as one of the only FDA-approved peptide medications. It's marketed as Vylessi for female sexual dysfunction. PT-141 works through melanocortin receptor activation to enhance sexual arousal and function. The peptide has demonstrated efficacy in clinical trials and has been approved by the FDA. However, its use was restricted to the branded product Vylessi, and compounding pharmacies couldn't prepare it. The reclassification allows compounding pharmacies to now prepare PT-141, potentially making it more accessible and affordable while also allowing it to be used off-label for male sexual dysfunction and other applications under physician supervision.

Specialized Therapeutic Peptides: GHK-Cu, AOD-9604, KPV, and MOTS-c

GHK-Cu is a copper-peptide complex that supports skin health, collagen production, and wound healing. It's been used in dermatology and anti-aging medicine for its ability to promote skin repair and rejuvenation. GHK-Cu appears to work by upregulating genes involved in skin health and collagen synthesis. Many aestheticians and dermatologists have used it off-label for skin rejuvenation. The reclassification means physicians can now legally prescribe it for skin health applications in conjunction with compounding pharmacies.

AOD-9604 is a fragment of growth hormone that specifically targets fat metabolism without the systemic effects of full growth hormone. It supports weight loss by enhancing fat cell apoptosis (death) and increasing fat burning while potentially preserving muscle mass. AOD-9604 has been extensively studied for obesity and weight management. It's particularly appealing because it provides growth hormone's fat-burning benefits without the muscle growth and insulin-related effects that full GH produces. The reclassification allows it to be legally prescribed and compounded for weight management protocols.

KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone that shows significant anti-inflammatory properties. It's been studied for applications in inflammatory bowel disease, intestinal health, and systemic inflammation. KPV appears to work through melanocortin receptor activation to suppress inflammatory signaling. Some research suggests it may be beneficial for patients with ulcerative colitis, Crohn's disease, and other inflammatory conditions. The reclassification allows healthcare providers to prescribe it for these therapeutic applications.

MOTS-c is a mitochondrial-derived peptide that supports cellular energy production and metabolic health. It enhances mitochondrial function, supports insulin sensitivity, and may have applications in metabolic disorders and aging. As a mitochondrial peptide, MOTS-c offers a unique mechanism of action targeting the very powerhouses of our cells. Preliminary research suggests it may be beneficial for metabolic syndrome, obesity, and age-related metabolic decline. Its reclassification opens opportunities for healthcare providers to use it in metabolic optimization protocols.

The 5 Peptides That Remain Banned (Category 2)

While 14 peptides are being reclassified, it's important to acknowledge that 5 of the original 19 banned peptides remain in Category 2. These peptides were not included in the reclassification, either because they have less scientific support, higher perceived risk, or require additional review. RFK Jr. indicated that these five are under continued review and may be reclassified in the future as additional evidence emerges.

The decision to maintain the ban on these five reflects a measured, evidence-based approach. Rather than deregulating all peptides indiscriminately, the FDA and HHS carefully evaluated each compound individually. This approach is actually more scientifically rigorous than either a blanket ban or complete deregulation would be. Patients interested in peptides for their specific health concerns should focus on the 14 now-available peptides, which provide substantial options for most therapeutic goals.

Future reclassification of the remaining five may depend on additional clinical data, long-term safety studies, or changing risk-benefit analyses. Healthcare providers and patients should monitor FDA announcements for any updates on the status of these peptides. For now, only the 14 peptides listed above are legally available for compounding.

Understanding Category 1 vs Category 2 Under 503A and 503B Rules

The FDA's compounding regulations exist to ensure that pharmacies preparing customized medications do so safely and effectively. The categories determine what compounds pharmacies are allowed to compound and under what circumstances.

Category 1 compounds are those approved by the FDA as finished drugs, or those with sufficient scientific evidence to support their safety and quality when compounded. This means a licensed compounding pharmacy can prepare these compounds under physician supervision with appropriate quality assurance. The pharmacy must follow Good Compounding Practices (GCP), use appropriate equipment, conduct sterility testing, and maintain detailed records. Patients receive medications prepared to pharmaceutical standards with documented potency and purity.

Category 2 compounds, by contrast, are considered to have insufficient evidence for safe compounding. No pharmacy in the United States can legally compound them, regardless of whether a patient has a prescription. This creates a complete prohibition on legal access through the pharmaceutical supply chain. Before the 2026 reclassification, all 19 peptides mentioned above were in Category 2. Now 14 have moved to Category 1, creating a dramatic shift in legal status and availability.

The difference between Category 1 and Category 2 is not about whether a compound is "safe" in an absolute sense—all medications carry some risk. Rather, it's about whether there's sufficient evidence to support safe compounding by pharmacies under physician supervision. Category 1 means yes, sufficient evidence exists. Category 2 means no, evidence is insufficient for this determination. This distinction is crucial for understanding what the reclassification means.

Why These Peptides Were Banned in 2023

In 2023, the FDA took the unusual step of banning 19 peptides from compounding. The stated reasons included concerns about the quality of compounded peptide formulations, the proliferation of counterfeit and contaminated products in the market, lack of FDA approval for these compounds, and safety concerns related to their use. The blanket approach meant all peptides were treated as equally risky, without distinction between those with strong scientific support and those with minimal evidence.

The 2023 ban was controversial from its inception. Many healthcare providers and patients felt it was overly restrictive and prevented access to compounds with substantial scientific support. Compounding pharmacy organizations argued that they could prepare peptides safely under appropriate quality standards. Patients who had benefited from peptide therapy worried about losing legal access. This backlash created pressure for reconsideration, which ultimately led to the 2026 reclassification.

The current reclassification represents a more nuanced approach. Instead of blanket bans or complete deregulation, the FDA now evaluates each peptide individually based on scientific evidence, safety data, and risk-benefit analysis. This approach is more aligned with how evidence-based medicine should work: assess each compound on its merits rather than treating entire classes the same.

Timeline of Peptide Regulation Changes

Understanding the regulatory history helps contextualize the 2026 reclassification. Prior to 2023, peptides existed in a gray area of American medicine. They weren't FDA-approved as finished drugs for most applications, but they were available from compounding pharmacies under physician supervision. Many healthcare providers prescribed them, and patients accessed them through legal pharmaceutical channels.

In 2023, the FDA's decisive action to ban 19 peptides from compounding created a sudden prohibition. This ban was broadly interpreted as reflecting serious safety concerns, though the actual justification was more nuanced. The ban forced patients who wanted peptide therapy to either stop using peptides or access them through gray-market suppliers, which carried quality and legal risks.

Between 2023 and early 2026, advocacy for reclassification grew. Patient groups, healthcare provider organizations, and compounding pharmacy representatives submitted comments to the FDA detailing the scientific evidence and clinical experience supporting many of the banned peptides. This advocacy, combined with changing political administration priorities, created the conditions for reconsideration.

On February 27, 2026, RFK Jr.'s announcement on the Joe Rogan Experience revealed the FDA's decision to reclassify 14 of the 19 peptides. This move is expected to be formalized through official FDA regulatory channels, but the announcement signaled the shift in policy. Going forward, patients and healthcare providers should expect that these 14 peptides are now legally available through compounding pharmacies with appropriate prescriptions and medical supervision.